GB1575545A - Tumour antigen and process for the preparation thereof - Google Patents
Tumour antigen and process for the preparation thereof Download PDFInfo
- Publication number
- GB1575545A GB1575545A GB18430/77A GB1843077A GB1575545A GB 1575545 A GB1575545 A GB 1575545A GB 18430/77 A GB18430/77 A GB 18430/77A GB 1843077 A GB1843077 A GB 1843077A GB 1575545 A GB1575545 A GB 1575545A
- Authority
- GB
- United Kingdom
- Prior art keywords
- tumour
- antigen
- group
- supernatant
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 55
- 238000000034 method Methods 0.000 title claims description 46
- 239000000427 antigen Substances 0.000 title claims description 42
- 102000036639 antigens Human genes 0.000 title claims description 42
- 108091007433 antigens Proteins 0.000 title claims description 42
- 230000008569 process Effects 0.000 title claims description 36
- 238000002360 preparation method Methods 0.000 title claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 29
- 239000006228 supernatant Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 13
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 239000013049 sediment Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 208000037841 lung tumor Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 4
- 229950004354 phosphorylcholine Drugs 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical group OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 claims description 2
- 238000011735 C3H mouse Methods 0.000 claims description 2
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 238000011785 NMRI mouse Methods 0.000 claims description 2
- 230000001133 acceleration Effects 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000243 solution Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762619715 DE2619715A1 (de) | 1976-05-04 | 1976-05-04 | Tumor-antigen und verfahren zu dessen herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1575545A true GB1575545A (en) | 1980-09-24 |
Family
ID=5977057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB18430/77A Expired GB1575545A (en) | 1976-05-04 | 1977-05-03 | Tumour antigen and process for the preparation thereof |
Country Status (17)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544512A (en) * | 1980-10-22 | 1985-10-01 | Takeda Chemical Industries, Ltd. | Tridecyloxy- or tetradecyloxy-propane derivatives |
| US4649203A (en) * | 1983-10-11 | 1987-03-10 | Takeda Chemical Industries, Ltd. | Ketoalkylphospholipids |
| US4889953A (en) * | 1986-07-22 | 1989-12-26 | Takeda Chemical Industries, Ltd. | Glycerol derivatives, their production and use |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551532A (en) * | 1980-05-08 | 1985-11-05 | Takeda Chemical Industries, Ltd. | Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity |
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| JPS58138383A (ja) * | 1982-02-13 | 1983-08-17 | Nippon Shinyaku Co Ltd | 生理活性物質の製法 |
| US4562179A (en) * | 1982-04-19 | 1985-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, and pharmaceutical composition of the same |
| JPS5933223A (ja) * | 1982-08-20 | 1984-02-23 | Koken Kk | 人の悪性腫瘍細胞増殖抑制剤 |
| US5030733A (en) * | 1987-07-23 | 1991-07-09 | Hoechst-Roussel Pharmaceticals Incorporated | Hydroxy-, alkoxy- and benzyloxy-substituted phospholipids |
| US5145844A (en) * | 1987-07-23 | 1992-09-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Methods of using hydroxy-, alkoxy- and benzyloxy-substituted phospholipids to treat phospholipase A2 -mediated conditions and to alleviate pain |
| US5036152A (en) * | 1988-03-10 | 1991-07-30 | Hoechst-Roussel Pharmaceuticals Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| US4888328A (en) * | 1988-03-10 | 1989-12-19 | Hoeschst-Roussel Incorporated | Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids |
| DE3906952A1 (de) * | 1989-03-04 | 1990-09-06 | Boehringer Mannheim Gmbh | (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel |
-
1976
- 1976-05-04 DE DE19762619715 patent/DE2619715A1/de not_active Withdrawn
-
1977
- 1977-04-29 NL NL7704724A patent/NL7704724A/xx not_active Application Discontinuation
- 1977-05-02 SE SE7705070A patent/SE7705070L/xx unknown
- 1977-05-02 IL IL51989A patent/IL51989A/xx unknown
- 1977-05-02 IT IT23093/77A patent/IT1074325B/it active
- 1977-05-02 NZ NZ183980A patent/NZ183980A/xx unknown
- 1977-05-03 AU AU24818/77A patent/AU517395B2/en not_active Expired
- 1977-05-03 CA CA277,457A patent/CA1077840A/en not_active Expired
- 1977-05-03 AT AT313277A patent/AT362497B/de not_active IP Right Cessation
- 1977-05-03 LU LU77245A patent/LU77245A1/xx unknown
- 1977-05-03 GB GB18430/77A patent/GB1575545A/en not_active Expired
- 1977-05-03 IE IE887/77A patent/IE44943B1/en unknown
- 1977-05-03 DK DK194477A patent/DK194477A/da not_active Application Discontinuation
- 1977-05-04 BE BE177279A patent/BE854269A/xx not_active IP Right Cessation
- 1977-05-04 FR FR7713521A patent/FR2391733A1/fr active Granted
- 1977-05-04 JP JP5194377A patent/JPS52134011A/ja active Pending
- 1977-05-05 ZA ZA00772648A patent/ZA772648B/xx unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544512A (en) * | 1980-10-22 | 1985-10-01 | Takeda Chemical Industries, Ltd. | Tridecyloxy- or tetradecyloxy-propane derivatives |
| US4649203A (en) * | 1983-10-11 | 1987-03-10 | Takeda Chemical Industries, Ltd. | Ketoalkylphospholipids |
| US4889953A (en) * | 1986-07-22 | 1989-12-26 | Takeda Chemical Industries, Ltd. | Glycerol derivatives, their production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| DK194477A (da) | 1977-11-05 |
| IL51989A0 (en) | 1977-07-31 |
| AU517395B2 (en) | 1981-07-30 |
| FR2391733B1 (enrdf_load_stackoverflow) | 1980-03-07 |
| AU2481877A (en) | 1978-11-09 |
| AT362497B (de) | 1981-05-25 |
| ATA313277A (de) | 1980-10-15 |
| CA1077840A (en) | 1980-05-20 |
| LU77245A1 (enrdf_load_stackoverflow) | 1977-12-13 |
| NL7704724A (nl) | 1977-11-08 |
| IE44943B1 (en) | 1982-05-19 |
| SE7705070L (sv) | 1977-11-05 |
| JPS52134011A (en) | 1977-11-09 |
| ZA772648B (en) | 1978-04-26 |
| IE44943L (en) | 1977-11-04 |
| NZ183980A (en) | 1980-04-28 |
| FR2391733A1 (fr) | 1978-12-22 |
| IT1074325B (it) | 1985-04-20 |
| BE854269A (fr) | 1977-11-04 |
| DE2619715A1 (de) | 1977-11-24 |
| IL51989A (en) | 1980-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1575545A (en) | Tumour antigen and process for the preparation thereof | |
| US4931275A (en) | Anti-tumor vaccines and their preparation | |
| EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| CA1280693C (en) | Purification of pertussis antigens | |
| US4788058A (en) | B. pertussis vaccine production using carbodiimides | |
| US4239498A (en) | Method of preparing thymic factors and composition | |
| US3395219A (en) | Process for production of pertussis antigen | |
| EP0080021B1 (en) | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine | |
| KR970002614B1 (ko) | 백일해 내독소의 제거방법, 백일해 톡소이드 및 그 제조방법 | |
| US4220638A (en) | Antigenic complex from N. Gonorrhoeae | |
| US4341697A (en) | Antigenic material | |
| JPH04501853A (ja) | 大型多価免疫原 | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| EP0015846B1 (en) | Antigenic sub-cellular cell wall fraction of bordetella bronchiseptica, method of obtaining it and composition comprising it | |
| EP3672606A1 (en) | Mesenchymal stem/stromal cell-derived extracellular vesicles and uses thereof in autoimmune diseases | |
| US5885570A (en) | Induction of tolerance with modified immunogens | |
| JPS6211090A (ja) | トレポネマ・ハイオジセンテリアエの生育方法 | |
| Reinertsen et al. | In vivo immune response suppression by the supernatant from concanavalin A-activated spleen cells | |
| EP0004137B1 (en) | Immunogenic cell envelope preparations | |
| US4288557A (en) | Antigenic complex from N. gonorrhoeae | |
| US2965543A (en) | Alcohol detoxification of pertussis vaccines | |
| US4758517A (en) | Process for growth of treponema hyodysenteriae | |
| EP0002645B1 (en) | Antigenic complex from neisseria gonorrhoeae, process and vaccine | |
| AU772142B2 (en) | Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (GCS) | |
| EP0220988A1 (fr) | Procédé de culture de Babesia canis, application à la préparation d'antigènes et de vaccins, et antigènes et vaccins contre la piroplasmose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |